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Background: The randomised phase III TANIA trial demonstrated that continuing bevacizumab with second-line
chemotherapy for locally recurrent/metastatic breast cancer (LR/mBC) after progression on ﬁrst-line bevacizumab-
containing therapy signiﬁcantly improved progression-free survival (PFS) compared with chemotherapy alone [hazard
ratio (HR) = 0.75, 95% conﬁdence interval (CI) 0.61–0.93]. We report ﬁnal results from the TANIA trial, including overall sur-
vival (OS) and health-related quality of life (HRQoL).
Patients and methods: Patients with HER2-negative LR/mBC that had progressed on or after ﬁrst-line bevacizumab
plus chemotherapy were randomised to receive standard second-line chemotherapy either alone or with bevacizumab.
At second progression, patients initially randomised to bevacizumab continued bevacizumab with their third-line chemo-
therapy, but those randomised to chemotherapy alone were not allowed to cross over to receive third-line bevacizumab.
The primary end point was second-line PFS; secondary end points included third-line PFS, combined second- and third-
line PFS, OS, HRQoL and safety.
Results: Of the 494 patients randomised, 483 received second-line therapy; 234 patients (47% of the randomised
population) continued to third-line study treatment. The median duration of follow-up at the ﬁnal analysis was
32.1 months in the chemotherapy-alone arm and 30.9 months in the bevacizumab plus chemotherapy arm. There was
no statistically signiﬁcant difference between treatment arms in third-line PFS (HR = 0.79, 95% CI 0.59–1.06), combined
second- and third-line PFS (HR = 0.85, 95% CI 0.68–1.05) or OS (HR = 0.96, 95% CI 0.76–1.21). Third-line safety results
showed increased incidences of proteinuria and hypertension with bevacizumab, consistent with safety results for the
second-line treatment phase. No differences in HRQoL were detected.
Conclusions: In this trial, continuing bevacizumab beyond ﬁrst and second progression of LR/mBC improved second-
line PFS, but no improvement in longer term efﬁcacy was observed. The second-line PFS beneﬁt appears to be achieved
without detrimentally affecting quality of life.
ClinicalTrials.gov: NCT01250379.
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introduction
Several randomised phase III trials have demonstrated that com-
bining bevacizumab with chemotherapy improves progression-
free survival (PFS) in patients with locally recurrent/metastatic
breast cancer (LR/mBC) treated in either the ﬁrst-line or the
second-line setting [1–5]. The open-label randomised phase III
TANIA trial (NCT01250379) evaluated second-line bevacizu-
mab-containing therapy in patients with bevacizumab-pre-
treated LR/mBC [6]. As described previously [6], the biological
and preclinical rationale for sustained inhibition of vascular
endothelial growth factor (VEGF) is based on the crucial role of
VEGF throughout the angiogenic pathway. Furthermore, two
randomised trials in colorectal cancer indicated signiﬁcant
improvements in efﬁcacy with bevacizumab re-exposure after
progression on previous bevacizumab-containing therapy [7, 8].
The primary end point (second-line PFS) of the TANIA trial
was reported together with second-line safety results at the time
of the primary PFS analysis (data cut-off 20 December 2013)
[6]. The primary objective was met: second-line PFS was statis-
tically signiﬁcantly improved in patients receiving further beva-
cizumab [hazard ratio (HR) = 0.75, 95% conﬁdence interval
(CI) 0.61–0.93; P = 0.0068; median: 6.3 months (95% CI 5.4–
7.2) with bevacizumab versus 4.2 months (95% CI 3.9–4.7) with
chemotherapy alone]. Efﬁcacy and safety results relating to the
third-line treatment period and overall survival (OS) were not
mature at the time of primary end point disclosure. Here we
report third-line PFS, third-line safety and OS results at the ﬁnal
analysis, as well as health-related quality of life (HRQoL).
patients andmethods
study design
The trial design has previously been described in detail [6]. Brieﬂy, patients
with HER2-negative LR/mBC whose disease had progressed on or after ﬁrst-
line bevacizumab combined with chemotherapy were randomised to receive
standard second-line chemotherapy either alone or in combination with bev-
acizumab 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks, depending on
the selected chemotherapy schedule. The stratiﬁcation factors were hormone
receptor status (triple negative versus oestrogen and/or progesterone recep-
tor positive), ﬁrst-line PFS (<6 versus ≥6 months), choice of chemotherapy
(taxane versus non-taxane versus vinorelbine) and lactate dehydrogenase
concentration at baseline (≤1.5 versus >1.5× upper limit of normal). At
second tumour progression according to Response Evaluation Criteria in
Solid Tumours (RECIST) version 1.1, patients initially randomised to
chemotherapy alone received third-line chemotherapy without bevacizumab
(crossover not permitted), whereas patients initially randomised to bevacizu-
mab plus chemotherapy received third-line chemotherapy with continued
bevacizumab.
end points and statistics
The primary end point was investigator-assessed, second-line PFS (pub-
lished previously). Secondary end points included third-line PFS, combined
second- and third-line PFS (from randomisation until third progression/
death), OS (from randomisation until death from any cause), HRQoL and
safety. PFS and OS were compared between treatment groups with a two-
sided log-rank test, stratiﬁed by the four stratiﬁcation factors mentioned
above. Median values in each treatment arm were estimated using the
Kaplan–Meier method. A stratiﬁed Cox proportional hazards model was
used to estimate the HR with 95% CIs.
Tumours were assessed by investigators (based on limited RECIST
version 1.1) every 8 or 9 weeks, coinciding with patients’ treatment visits
according to the chosen chemotherapy (every 3-week or every 4-week sched-
ule) to minimise inconvenience to patients. There was no independent
review of PFS. HRQoL was assessed using the Functional Assessment of
Cancer Therapy—Breast (FACT-B) administered at baseline, every 8/9 weeks
(depending on treatment schedule) during second-line therapy, and at the
time of second progression. HRQoL analyses included differences between
treatment arms in mean change from baseline for each FACT-B subscale;
when designing the HRQoL analyses, physical and functional well-being
subscales were considered prospectively to be the most relevant subscales in
this setting [9]. Subscale scores were calculated only if at least 50% of items
in the subscale were not missing. FACT-B Trial Outcome Index (TOI),
FACT-General and FACT-B total scores were calculated only if at least 80%
of the corresponding items were not missing. Missing questionnaires were
imputed at every time point before or at the ‘end of QoL reporting period’
date to which no questionnaires were assigned. In exploratory responder
analyses based on methods and cut-offs described in the literature [10, 11],
patients were categorised as having ‘improved’ (≥3-point improvement),
‘worsened’ (≥3-point deterioration) or ‘stable’ (change of <3 points) HRQoL
and the proportions of patients in each category at each time point were
calculated.
Third-line efﬁcacy analyses were based on the third-line efﬁcacy popula-
tion, comprising all patients who received at least one dose of third-line
study therapy. Third-line safety was analysed according to the treatment
actually received in the third-line treatment phase (bevacizumab versus
no bevacizumab) rather than by the treatment to which each patient was
randomised for second-line treatment. Analyses of combined second- and
third-line PFS and OS were based on the intent-to-treat population.
The ﬁnal analysis was carried out as planned, when all patients had been
followed for at least 24 months since randomisation (or died, withdrawn
consent or been lost to follow-up).
results
patient population and follow-up
Of the 494 patients randomised to second-line therapy, 234 (47%)
received at least one dose of third-line therapy (Figure 1; supple-
mentary Appendix Table S1, available at Annals of Oncology
online). At the time of data cut-off for the ﬁnal analysis (30 April
2015), the median duration of follow-up was 32.1 months [inter-
quartile range (IQR) 25.1–36.9 months] in the chemotherapy-alone
arm and 30.9 months (IQR 26.4–37.1 months) in the bevacizumab-
containing arm.
treatment exposure
All patients had stopped all study treatment by the time of data
cut-off for this analysis.
The median duration of chemotherapy in the second-line
safety population was 3.9 months (range <0.1–36.3 months)
in the chemotherapy-alone arm and 4.4 months (range <0.1–
33.2 months) in the bevacizumab-containing arm. Median
second-line bevacizumab exposure in the combination arm
was 4.5 months (range <0.1–33.1 months).
In the third-line setting, the chemotherapy regimens most
commonly selected by the investigators were vinorelbine (33%
of the chemotherapy-alone arm versus 31% of the bevacizumab-
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containing arm), capecitabine (10% versus 15%, respectively)
and non-pegylated liposomal doxorubicin (16% versus 13%, re-
spectively). The median duration of third-line chemotherapy
was shorter than second-line chemotherapy in both treatment
arms: 2.1 months (range <0.1–20.0 months) in the chemother-
apy-alone arm and 2.6 months (range 0.2–14.3 months) in the
bevacizumab-containing arm. The median duration of third-
line bevacizumab was 2.1 months (range <0.1–22.1 months).
The extent and type of post-study therapy administered were
quite similar in the two treatment arms. In the chemotherapy-
alone arm, 68% of patients in the third-line population had
received further chemotherapy after tumour progression, most
commonly eribulin (30%), cyclophosphamide (17%), vinorel-
bine (15%), gemcitabine (13%) or doxorubicin (12%). In the
bevacizumab-containing arm, 60% of patients in the third-line
population had received further chemotherapy after progression,
most commonly eribulin (29%), doxorubicin (16%), vinorel-
bine, cyclophosphamide or gemcitabine (each 12%). Endocrine
therapy was administered after third-line progression in 26% of
the chemotherapy-alone arm versus 29% of the bevacizumab-
containing arm. Everolimus was administered in 10% versus
3%, respectively.
efﬁcacy
There was no statistically signiﬁcant difference in third-line PFS
between the two treatment arms (Figure 2A). No differences
between treatment arms were observed for either combined
second- and third-line PFS (Figure 2B) or OS (Figure 2C).
The Kaplan–Meier curve for third-line PFS showed that in
both treatment arms, almost half the patients entering third-line
therapy experienced a PFS event within the ﬁrst 3 months of
therapy. The subgroup of patients with early progression on
third-line therapy included higher proportions of patients with
triple-negative disease, ﬁrst-line PFS of <6 months and no prior
endocrine therapy than the overall population randomised to
second-line therapy. However, this comparison was based on
patient and disease characteristics before randomisation to
second-line therapy rather than immediately before third-line
therapy.
Results of subgroup analyses of third-line PFS, combined
second- and third-line PFS, and OS (which were not adjusted for
multiple testing) were generally consistent with those in the overall
population (supplementary Appendix Figure S1, available at
Annals of Oncology online). An exploratory analysis of second-line
PFS (at the time of ﬁnal data cut-off rather than the prespeciﬁed
primary analysis cut-off) indicated that the PFS beneﬁt from beva-
cizumab observed at the primary PFS analysis was sustained with
longer follow-up (HR = 0.79; 95% CI 0.65–0.97; P = 0.0204).
Median second-line PFS was 6.3 months (95% CI 5.5–7.6 months)
with bevacizumab-containing therapy versus 4.2 months (95% CI
3.9–5.3 months) with chemotherapy alone.
safety
Seventeen patients initially randomised to and treated with bev-
acizumab in the second-line setting received no bevacizumab
with their third-line chemotherapy [predominantly because of
adverse events preventing continuation of bevacizumab (persist-
ent proteinuria or hypertension, grade 2/3 venous embolism,
osteonecrosis of the jaw)] and were therefore included in the
chemotherapy-alone arm for safety analyses.
Third-line safety results were consistent with observations in
the second-line safety population reported at the time of the
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Figure 1. Patient disposition and analysis populations. aIntent-to-treat population. bOne patient re-randomised by mistake, one patient had HER2-positive
disease. BEV, bevacizumab; CT, chemotherapy.
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primary analysis [6]. Adverse events (all grades) were more
common with bevacizumab-containing therapy than chemo-
therapy alone (81% versus 63%, respectively), driven mainly by
higher incidences of proteinuria (23% versus 13%, respectively)
and hypertension (20% versus 4%) (supplementary Appendix
Table S2, available at Annals of Oncology online). Grade ≥3
adverse events were reported in 62% versus 43%, respectively,
including grade ≥3 hypertension in 10% versus 2%, respectively.
During third-line therapy there were three fatal adverse events:
two in the chemotherapy-alone arm (cardiac failure in one
patient, ischaemic cardiomyopathy in the other; both treated
with second-line capecitabine and third-line doxorubicin) and
one in the bevacizumab-containing arm (multi-organ failure in
a patient treated with second-line capecitabine and third-line
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Figure 2. Final efﬁcacy results (stratiﬁed by hormone receptor status, ﬁrst-line PFS, choice of chemotherapy and lactate dehydrogenase level). (A) Third-line
PFS from start of third-line therapy (third-line efﬁcacy population); (B) combined second- and third-line PFS from randomisation (intent-to-treat population);
(C) ﬁnal OS (intent-to-treat population). BEV, bevacizumab; CI, conﬁdence interval; CT, chemotherapy; HR, hazard ratio; PFS, progression-free survival; OS,
overall survival.
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vinorelbine). In the third-line safety follow-up period, there
were two further fatal adverse events (mitral valve incompetence
and congestive heart failure), both in the chemotherapy-alone
arm.
health-related quality of life
Compliance with questionnaire completion was similar in the
two treatment arms and was 68%–75% between weeks 8/9 and
24/27 (supplementary Appendix Figure S2, available at Annals
of Oncology online). Mixed-model repeated-measures analyses
of change from baseline at week 8/9 and overall showed no
meaningful differences between treatment arms for any of the
subscales (supplementary Appendix Table S3, available at
Annals of Oncology online).
For functional well-being, the change from baseline across all
time points was almost identical in the two treatment arms
(Figure 3A). For physical well-being, 95% CIs were overlapping
at almost all time points, and numerical differences were not
clinically meaningful (Figure 3B).
Exploratory responder analyses of the Breast Cancer subscale,
FACT-B composite TOI total score, FACT-General TOI total
score and FACT-B total score showed no difference between the
treatment arms (data not shown). Exploratory analysis of the
best response for physical well-being over time also showed no
difference between treatment arms (supplementary Appendix
Table S4, available at Annals of Oncology online).
discussion
Although patients treated with bevacizumab after progression
on ﬁrst-line bevacizumab-containing therapy beneﬁted in terms
of second-line PFS compared with patients treated with chemo-
therapy alone [6], no signiﬁcant improvement in third-line PFS
or OS (secondary end points) was observed with longer continu-
ation of bevacizumab. The concept of treatment beyond pro-
gression is well established in LR/mBC: for many years, before
the availability of alternative anti-HER2 therapies, a standard
approach at the time of progression on trastuzumab-containing
A
–5
–4
–3
–2
–1
0
1
2
3
4
5
6
Week
8/9
Week
16/18
Week
24/27
Week
32/36
Week
40/45
Week
48/54
2nd-line
progression
CT (N = 247)
BEV + CT (N = 247)
No. of patients
CT 117 75 42 25 18 13 80
BEV + CT 128 98 72 40 25 20 76
–0.01
(–1.14 to 1.12)
0.03
(–1.38 to 1.45)
–0.06
(–1.90 to 1.78)
0.26
(–2.31 to 2.82)
–0.56
(–3.14 to 2.02)
–0.68
(–4.06 to 2.70)
0.64
(–0.92 to 2.20)
Improvement
Worsening
M
ea
n 
ch
an
ge
 fr
om
 b
as
el
in
e 
(95
% 
CI
)
B
M
ea
n 
ch
an
ge
 fr
om
 b
as
el
in
e 
(95
% 
CI
)
–5
–4
–3
–2
–1
0
1
2
3
4
5
6
Week
8/9
Week
16/18
Week
24/27
Week
32/36
Week
40/45
Week
48/54
2nd-line
progression
CT (N = 247)
BEV + CT (N = 247)
No. of patients
CT 118 77 44 25 18 13 81
BEV + CT 125 97 73 39 25 20 77
–0.01
(–1.34 to 1.32)
–2.12
(–3.60 to –0.64)
–2.18
(–4.17 to –0.18)
–2.12
(–4.49 to 0.26) –0.82(–3.96 to 2.33)
–3.13
(–6.52 to 0.26)
–1.64
(–3.27 to –0.01)
Improvement
Worsening
Figure 3. Mean change from baseline in Functional Assessment of Cancer Therapy—Breast subscales: (A) Functional well-being; (B) physical well-being.
Numbers above plots represent between-treatment group comparisons for each time point with corresponding 95% CIs. BEV, bevacizumab; CI, conﬁdence
interval; CT, chemotherapy.
 | Vrdoljak et al. Volume 27 | No. 11 | November 2016
original articles Annals of Oncology
therapy for HER2-positive mBC was to continue trastuzumab
and switch to a different chemotherapy regimen [12]. An im-
portant difference between the TANIA trial and the GBG26 trial
(which evaluated trastuzumab treatment beyond progression
[13]) was the control of third-line as well as second-line therapy
in TANIA, prohibiting crossover to bevacizumab from the
chemotherapy-alone arm at second progression. This feature of
the trial design was implemented to try to limit the confounding
effect of subsequent lines of therapy. Nevertheless, as 150 (64%)
of the 234 patients who entered the third-line portion of the
TANIA trial subsequently received further chemotherapy or tar-
geted therapy, the likely impact of subsequent lines of treatment
is not negligible.
Another challenge when assessing longer term outcomes,
such as third-line PFS, is the substantial attrition between
second progression and third-line therapy. Of the 494 patients
randomised, 483 received second-line study therapy but only
234 (47% of all randomised patients) received third-line study
therapy. When interpreting OS, it should be noted that more
than half of the population did not receive third-line study
therapy and 13% of those entering the third-line bevacizumab
treatment phase did not receive bevacizumab. Consequently, in
effect the trial tested continuation of bevacizumab into third-
line treatment in only 112 (45%) of the 247 patients initially ran-
domised to bevacizumab-containing therapy.
As with many other contemporary trials in HER2-negative
LR/mBC, including previous trials evaluating the addition of
bevacizumab to chemotherapy, the PFS beneﬁt did not translate
into an OS improvement. The challenges of demonstrating an
OS beneﬁt in mBC and other tumour types with long post-pro-
gression survival have been discussed extensively in the litera-
ture [14, 15]. Furthermore, the TANIA trial was not powered to
demonstrate differences in secondary efﬁcacy end points.
Additional limitations include the open-label trial design and
investigator assessment of PFS.
None of the analysed subgroups appeared to derive a particu-
larly large or small beneﬁt from bevacizumab consistently across
end points, although these analyses were limited by their ex-
ploratory nature and dependence on characteristics deﬁned
before second-line progression. Analysis of plasma biomarker
concentrations at baseline also failed to identify subgroups of
patients who may beneﬁt most or least from bevacizumab [16].
Analysis of tissue markers is ongoing.
The proportion of patients completing HRQoL question-
naires was quite high at the start of the study, although at later
time points only a small proportion of patients completed ques-
tionnaires (explained in part by attrition due to progressive
disease). HRQoL analyses showed no detectable differences
between treatment arms during second-line therapy, suggesting
that the second-line PFS beneﬁt with bevacizumab is achieved
with maintained HRQoL. The main limitations of the HRQoL
analyses were the open-label design of the trial, the lack of ques-
tionnaire collection after progression and, arguably, the choice
of questionnaire. In addition, there was no prespeciﬁed hypoth-
esis relating to HRQoL. Acknowledging the limitations of ana-
lyses based solely on comparing mean values or mean changes
from baseline, which may mask meaningful beneﬁt to individual
patients, we carried out responder analyses to determine the
proportion of patients with a substantial improvement in given
symptoms. These exploratory analyses also showed no differ-
ences between treatment arms.
The safety proﬁle of bevacizumab plus chemotherapy in the
third-line treatment period was consistent with the safety proﬁle
previously reported for second-line therapy in the TANIA trial
[6] and from extensive experience with bevacizumab-containing
therapy in earlier treatment settings reported in the literature
[1–4, 17]. Of note, even in the third-line setting, hypertension
was more common in patients receiving bevacizumab than in
those receiving chemotherapy alone. The association between
bevacizumab therapy and hypertension might be expected to di-
minish in later treatment lines, as patients with uncontrollable
hypertension would typically discontinue treatment, leaving a
population enriched with those able to tolerate bevacizumab.
However, bevacizumab-containing therapy was associated with
increased risk of hypertension even after prolonged exposure in
three treatment lines. Reassuringly there was no evidence of
increased cardiac toxicity with multiple lines of bevacizumab.
The results described here should be considered alongside
those of the primary PFS analysis. The TANIA trial demon-
strated that in patients with bevacizumab-pretreated LR/mBC,
continued bevacizumab signiﬁcantly improved second-line PFS,
thus meeting the primary objective of the trial. However, further
bevacizumab after second progression did not signiﬁcantly
improve third-line PFS or OS. In one of the ﬁrst trials of bevaci-
zumab in heavily pretreated disease [18], it was suggested that
the lack of bevacizumab treatment effect on PFS was perhaps
due to increased redundancy of angiogenic pathways in later
stages of the disease. This may partially explain the lack of de-
tectable effect in the third-line setting in TANIA. Alternative
treatments are required in this setting. Although few agents have
been evaluated speciﬁcally in chemotherapy- and bevacizumab-
pretreated disease, promising emerging options include CDK4/6
inhibitors, which have demonstrated efﬁcacy in earlier treatment
lines for hormone receptor-positive disease [19] and immu-
notherapeutic approaches, PARP inhibitors and approaches tar-
geting the androgen receptor in triple-negative breast cancer
[20, 21]. Overall, results from the TANIA trial demonstrate the
efﬁcacy of second-line bevacizumab in bevacizumab-pretreated
patients; however, further bevacizumab in the third-line setting
does not appear to improve outcomes further.
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